What is cerebral folate deficiency 

Cerebral folate deficiency (CFD) is a neurological condition defined by low levels of 5-methyltetrahydrofolate (5-MTHF), the active form of folate, in cerebrospinal fluid (CSF), even when folate levels in the blood are normal. Impaired transport defects or increasing need for folate turnover can lead to low folate levels in CSF.¹

Folate relies on folate receptor alpha (FRα), which is regulated by the FOLR1 gene, to cross the blood-brain barrier (BBB) into the brain. Disruption of folate transport may occur due to genetic discrepancies of the FOLR1 gene, post-translational defects of FRα protein N-glycosylation, and antibodies blocking the folate binding site of FRα. Other causes include chronic use of folate-depleting medications, such as anticonvulsant drugs, carbidopa, methotrexate, sulfasalazine, and trimethoprim, which can interfere with folate absorption or metabolism.²

Additionally, CFD has also been associated with several genetic and metabolic disorders, including Rett syndrome, Aicardi-Goutières syndrome, 3-phosphoglycerate dehydrogenase deficiency, dihydropteridine reductase deficiency, aromatic amino acid decarboxylase deficiency, and Kearns-Sayre syndrome.^3,4

The accurate prevalence of cerebral folate deficiency is unknown. Patients might present a range of neurologic symptoms, including neuropsychiatric conditions and movement disorders, at any age, depending on underlying causes. The delay of treatment leads to irreversible neurological consequences.^5,6

Most genetically related disorders affecting folate metabolism and transport are reported in children. Clinical symptoms typically emerge at 1-2 years and present developmental delays, movement disorders, seizures, and autistic features.⁷ In adults, cerebral folate deficiency presents a variety of symptoms, including cognitive impairment, memory loss, peripheral neuropathy, movement disorders, and sleep disturbances. The onset in adults can be gradual, and symptoms may mimic other neurodegenerative or psychiatric conditions, making diagnosis challenging.⁸ 

Family of folate

Vitamin B9 is essential for fertility, fetal development, and cognitive function and is involved in metabolism and the regulation of gene expression. The deficiency of folate could result in fatigue, anaemia, birth defects, and neurological issues. Vitamins B2, B6 and B12 are also crucial as cofactors for enzymes that convert folates into different active forms. As a result, adequate levels of these vitamins are necessary for these processes to function properly.^1,9 

There are several names related to Vitamin B9, including folate, folic acid, folinic acid, and methylfolate, which can be confusing.

Folate 

Folate is the natural form of vitamin B9 found in foods such as green leafy vegetables, sprouts, citrus fruits, and organ meats like liver. It is an essential water-soluble micronutrient in inactive form and must be converted in the body into active forms to function through a series of enzymatic steps. Folate is also sensitive to heat and can be easily degraded during the cooking process.

Folic acid 

Folic acid is a synthetic and inactive form of vitamin B9 used in dietary supplements. It is chemically more stable than natural folate. However, folic acid is inactive in the body and must undergo several enzymatic conversions in the liver, primarily through the dihydrofolate reductase pathway, before becoming active. In individuals with certain genetic variants (e.g., MTHFR polymorphisms), this conversion process may be inefficient, leading to lower levels of active folate despite supplementation with folic acid.

Folinic acid (5-formyl tetrahydrofolate) 

Folinic acid is an active form of vitamin B9 that occurs naturally in foods and is also available as a supplement or prescription medication. Unlike folic acid, folinic acid does not require initial enzymatic reduction steps and can be rapidly converted into active forms, making it a suitable treatment option for individuals with certain genetic mutations with folate metabolism defects.

Methylfolate (5-methyltetrahydrofolate, 5-MTHF) 

5-MTHF is a biologically active form of folate. It is the primary circulating form in the body and can be directly used in cellular processes, such as DNA synthesis and methylation. Methylfolate can be obtained directly from supplements or produced in the body from folinic acid or natural folates. Because it is already in an active form, methylfolate supplementation is especially valuable for individuals with impaired folate metabolism due to genetic variants or chronic illness.¹⁰ 

Rationale for using high-dose folinic acid

Normally, folinic acid is suggested to start at a lower dose (0.5-1 mg/kg/day), while some patients need higher daily doses (2-3 mg/kg/day) to normalise the levels of folate in CSF.^3,11 

For patients with FOLR1 gene mutation, which means their folate transport is restricted, folinic acid is suggested to be given at a starting dose of 2.5-5 mg/kg/day orally, and monitoring the folate level in CSF regularly.⁷ Several cases in children have been reported where the dose of folinic acid increases gradually from oral administration of 0.5 mg/kg/day up to 12-24 mg/kg/day intravenously in order to control seizures.^12,13

A case report described a 58-year-old woman with autoimmune cerebral folate deficiency who presented with progressive memory loss and myoclonus. She was treated with folinic acid at 25 mg/day for six months. By the end of treatment, her cerebrospinal fluid folate levels had returned to the normal range, and her neurological symptoms had improved.¹⁴

Folinic acid treatment can normalise the level of 5-MTHF in CSF and improve clinical neurological symptoms, such as movement disorders, gait, and behaviour. High-dose folinic acid can enter the cerebrospinal fluid by three possible mechanisms.

Direct conversion from folinic acid

Folinic acid, an active form of vitamin B9, does not require the action of dihydrofolate reductase for activation and can be rapidly converted into 5-methyltetrahydrofolate (5-MTHF), the physiologically active form of folate in the central nervous system. Because this conversion bypasses certain metabolic steps, it is particularly useful in genetic conditions or enzymatic defects that otherwise limit folate availability.

Competitive displacement at folate receptors

In autoimmune-related cases, antibodies bind to the folate receptor alpha (FRα) and prevent the transport of folate into the brain. However, when plasma concentrations of 5-MTHF are raised to very high levels through high-dose folinic acid supplementation, the active folate can outcompete these blocking antibodies for receptor binding. This competitive displacement allows enough 5-MTHF to cross into the CSF via receptor-mediated transport to restore or improve folate status in the brain.

Passive diffusion at supraphysiological concentrations

When plasma levels of 5-MTHF are driven to extremely high concentrations, folate can cross into the CSF through passive diffusion, a mechanism that does not rely on folate-specific transporters. Although this process is less efficient under normal physiological conditions, it becomes significant at high plasma concentrations and may contribute to CSF folate restoration in cases where receptor-mediated transport is severely impaired.¹⁵

There is no rational guideline for the management of cerebral folate deficiency; treatment is based on cases. Early intervention, especially before the onset of severe neurological symptoms, can lead to better outcomes. 

FAQs

How to diagnose cerebral folate deficiency?

Cerebral folate deficiency is a neurological syndrome caused by insufficient levels of vitamin B9 (folate) within the brain, which is characterised by a CSF 5-MTHF level < 5 nmol/L. The primary diagnostic approach is a lumbar puncture, in which a needle is inserted between spinal bones to collect cerebrospinal fluid. Folate levels in the CSF are measured and compared with plasma folate concentrations to help confirm the diagnosis and identify whether the deficiency is isolated to the brain or part of a systemic folate deficiency.

Is cerebral folate deficiency a genetic disorder? 

Cerebral folate deficiency is a condition with multiple possible causes. Some cases are related to genetic mutations that impair folate transport or metabolism, such as mutations in the FOLR1 gene or in enzymes involved in folate pathways. Other cases arise from non-genetic factors, including autoimmune antibodies against folate receptors, chronic use of certain medications, or gastrointestinal disorders that reduce folate absorption.

Is cerebral folate deficiency curable?

Yes. Many cases of cerebral folate deficiency can be effectively treated, and symptoms may improve or resolve with appropriate folate supplementation. The choice of folate form is important, since the condition often involves impaired folate transport or metabolism. Treatment typically uses folinic acid rather than standard folic acid, as these forms can bypass certain metabolic steps. Early diagnosis and prompt therapy are key to achieving the best neurological outcomes.

How long does it take to reverse folate deficiency?

The duration of treatment of cerebral folate deficiency varies depending on the severity of the deficiency, the underlying cause (e.g., genetic defect, autoantibody-mediated transport block, medication-related deficiency), and the presence of neurological symptoms. For some patients with genetic defects or autoimmune disease, lifelong folinic acid supplementation may be necessary to maintain adequate cerebrospinal fluid folate levels and prevent symptom recurrence.

Summary

Cerebral folate deficiency is a neurological condition characterised by a level of 5-MTHF in CSF below 5 nmol/L, accompanied by neurological symptoms. Its causes could be genetic mutations that impaired folate transport across the blood–brain barrier or defects in the enzymatic conversion of folate into its active form, as well as autoimmune mechanisms in which antibodies block folate receptor binding. The most effective treatment is folinic acid, with a suggested initial dose of 0.5-1 mg/kg/day administered orally. The dose and treatment duration can be adjusted according to clinical response and monitoring.